CA3249036A1 - CYCLIC PEPTIDES FOR ADMINISTERING THERAPEUTIC AGENTS - Google Patents
CYCLIC PEPTIDES FOR ADMINISTERING THERAPEUTIC AGENTSInfo
- Publication number
- CA3249036A1 CA3249036A1 CA3249036A CA3249036A CA3249036A1 CA 3249036 A1 CA3249036 A1 CA 3249036A1 CA 3249036 A CA3249036 A CA 3249036A CA 3249036 A CA3249036 A CA 3249036A CA 3249036 A1 CA3249036 A1 CA 3249036A1
- Authority
- CA
- Canada
- Prior art keywords
- side chain
- amino acid
- pct
- formula
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263363450P | 2022-04-22 | 2022-04-22 | |
| US63/363,450 | 2022-04-22 | ||
| US202263354471P | 2022-06-22 | 2022-06-22 | |
| US63/354,471 | 2022-06-22 | ||
| US202263377754P | 2022-09-30 | 2022-09-30 | |
| US63/377,754 | 2022-09-30 | ||
| PCT/US2023/019452 WO2023205451A1 (en) | 2022-04-22 | 2023-04-21 | Cyclic peptides for delivering therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3249036A1 true CA3249036A1 (en) | 2023-10-26 |
Family
ID=86332269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3249036A Pending CA3249036A1 (en) | 2022-04-22 | 2023-04-21 | CYCLIC PEPTIDES FOR ADMINISTERING THERAPEUTIC AGENTS |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250289851A1 (https=) |
| EP (1) | EP4511385A1 (https=) |
| JP (1) | JP2025513521A (https=) |
| CN (1) | CN119156395A (https=) |
| CA (1) | CA3249036A1 (https=) |
| WO (1) | WO2023205451A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326646A (en) | 2023-08-17 | 2026-04-01 | Entrada Therapeutics Inc | Intracellular targeting of oligonucleotides |
| WO2025038901A1 (en) | 2023-08-17 | 2025-02-20 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| JP2004537517A (ja) | 2001-05-17 | 2004-12-16 | エイブイアイ バイオファーマ， インコーポレイテッド | ｃ−ｍｙｃアンチセンスオリゴマーを使用した、癌を処置するための併用アプローチ |
| AU2002342057B2 (en) | 2001-10-16 | 2009-01-22 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| EP1713332A4 (en) | 2004-01-23 | 2010-08-18 | Avi Biopharma Inc | ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION |
| US7402574B2 (en) | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US8329668B2 (en) | 2005-09-08 | 2012-12-11 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| DK2735568T3 (da) | 2006-05-10 | 2017-11-13 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske bindinger mellem underenheder |
| EP3443976A1 (en) | 2007-06-29 | 2019-02-20 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| CN112574988A (zh) | 2008-10-24 | 2021-03-30 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| US20100210989A1 (en) | 2008-12-23 | 2010-08-19 | Janet Lesley Macpherson | Processing blood |
| RS55610B1 (sr) | 2010-09-30 | 2017-06-30 | Nippon Shinyaku Co Ltd | Derivat morfolino nukleinske kiseline |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| ES2727481T3 (es) | 2011-11-30 | 2019-10-16 | Sarepta Therapeutics Inc | Inclusión inducida de exón en atrofia muscular espinal |
| WO2014189142A1 (ja) | 2013-05-24 | 2014-11-27 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| EP3613426A1 (en) * | 2014-05-21 | 2020-02-26 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| TW202500573A (zh) * | 2016-11-22 | 2025-01-01 | 俄亥俄州立創新基金會 | 細胞穿透肽序列 |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| EP3672601B1 (en) | 2017-09-25 | 2023-09-13 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis |
| TW201945014A (zh) * | 2018-02-22 | 2019-12-01 | 美商安卓達治療股份有限公司 | 用於治療粒線體性神經胃腸腦病變之組合物及方法 |
| US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| US12012427B2 (en) | 2019-10-31 | 2024-06-18 | Indian Association For The Cultivation Of Science | Synthesis of Fmoc-protected morpholino monomers and their use in the synthesis of morpholino oligomer |
| CN117120456A (zh) | 2020-12-11 | 2023-11-24 | 卫材R&D管理有限公司 | 聚-吗啉代寡核苷酸缺口体 |
| US20240358845A1 (en) * | 2021-05-10 | 2024-10-31 | Entrada Therapeutics, Inc. | Compositions and methods for intracellular therapeutics |
| WO2023081893A1 (en) * | 2021-11-08 | 2023-05-11 | Entrada Therapeutics, Inc. | Intracellular targeting of oligonucleotides |
-
2023
- 2023-04-21 US US18/858,718 patent/US20250289851A1/en active Pending
- 2023-04-21 CN CN202380034351.1A patent/CN119156395A/zh active Pending
- 2023-04-21 WO PCT/US2023/019452 patent/WO2023205451A1/en not_active Ceased
- 2023-04-21 JP JP2024562265A patent/JP2025513521A/ja active Pending
- 2023-04-21 EP EP23723360.6A patent/EP4511385A1/en active Pending
- 2023-04-21 CA CA3249036A patent/CA3249036A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250289851A1 (en) | 2025-09-18 |
| CN119156395A (zh) | 2024-12-17 |
| WO2023205451A1 (en) | 2023-10-26 |
| JP2025513521A (ja) | 2025-04-24 |
| EP4511385A1 (en) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bird et al. | Synthesis and Biophysical Characterization of Stabilized α‐Helices of BCL‐2 Domains | |
| EP3143037B1 (en) | Alpha4beta7 integrin thioether peptide antagonists | |
| ES2430323T3 (es) | Construcciones de péptidos natriuréticos cíclicos | |
| CN102712675A (zh) | 拟肽大环化合物 | |
| AU2007233123A1 (en) | Linear natriuretic peptide constructs | |
| CA3249036A1 (en) | CYCLIC PEPTIDES FOR ADMINISTERING THERAPEUTIC AGENTS | |
| CN110267970A (zh) | 用于靶向各种选定器官或组织的物质 | |
| JP2021501201A (ja) | ステープルペプチドの細胞内送達のためのポリペプチド接合体 | |
| SK11242002A3 (sk) | Zlúčenina, spôsob prípravy zlúčeniny, farmaceutický prostriedok a spôsob liečenia rakoviny | |
| Dastpeyman et al. | Modular synthesis of trifunctional peptide-oligonucleotide conjugates via native chemical ligation | |
| US12171838B2 (en) | Polypeptide conjugates for intracellular delivery of nucleic acids | |
| EP4393959A1 (en) | Human transferrin receptor-binding antibody-peptide conjugate | |
| EP2569327B1 (en) | Eif4e binding peptides | |
| CN101505784B (zh) | 环状利尿钠肽构建体 | |
| US20250171776A1 (en) | Non-canonical cell-penetrating peptides for antisense oligomer delivery | |
| Yang | Applications of Benzotriazol-1-yloxy compounds in peptide synthesis | |
| TW202426031A (zh) | ＥｐｈＡ２結合待定肽及包含其之組成物 | |
| EP4501941A1 (en) | Peptide complex having trkb binding activity | |
| CN121362229A (zh) | 介导靶向利钠肽受体的多肽配体及其用途 | |
| AU2024325879A1 (en) | Intracellular targeting of oligonucleotides | |
| WO2026037285A1 (zh) | 一种肾脏靶向的多肽寡核苷酸缀合物及其应用 | |
| TW202504632A (zh) | 靶向磷脂醯肌醇蛋白聚糖－３之肽組成物及其用途 | |
| EP4667483A1 (en) | Human transferrin receptor-binding peptide | |
| CA2408885A1 (en) | Vectors for dna delivery | |
| HK1235801B (en) | Alpha4beta7 integrin thioether peptide antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241015 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241015 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241015 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241108 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241120 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241127 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241219 |